FierceBiotechOriginal article
{"a":[{"_":"China’s Henlius carves out $440M T-cell engager deal with Amberstone","$":{"href":"/biotech/chinas-henlius-carves-out-440m-t-cell-engager-deal-amberstone","hreflang":"en"}}]}
PartnershipPositive
AI Analysis
Summary
Henlius Biotech, a Fosun Pharma subsidiary, entered a $440 million biobucks deal with Amberstone Biosciences to develop T-cell engagers.
Importance:6/10
Sentiment:
0.50
partnershipT-cell engagercollaborationbiobucks deal
Related Companies
Read the original article
Published by FierceBiotech on September 24, 2026 10:03 AM
